KFAS
NTLA icon

Keating Financial Advisory Services’s Intellia Therapeutics NTLA Stock Holding History

Keating Financial Advisory Services’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.95K Sell
529
-200
-27% -$2.8K ﹤0.01% 1288
2026
Q1 		$9.35K Buy
729
+109
+18% +$1.39K ﹤0.01% 1161
2025
Q4 		$5.57K Buy
+620
New +$8.54K ﹤0.01% 1250

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Keating Financial Advisory Services's NTLA Position: Q2 2026 in Review

Keating Financial Advisory Services reduced its Intellia Therapeutics (NTLA) stake by 27% in Q2 2026, selling an estimated $2.8K and leaving 529 shares worth $8.95K. The position accounts for ﹤0.01% of the portfolio, ranked #1288.

Keating Financial Advisory Services first reported a position in NTLA in Q4 2025 and has held it in 3 quarters since. The position peaked at $9.35K in Q1 2026. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Keating Financial Advisory Services held 529 shares of Intellia Therapeutics worth $8.95K as of Q2 2026.
  • Keating Financial Advisory Services sold 200 Intellia Therapeutics shares in Q2 2026, an estimated $2.8K.
  • Intellia Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1288 holding.
  • Keating Financial Advisory Services first reported a position in Intellia Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Keating Financial Advisory Services's Intellia Therapeutics position peaked at $9.35K in Q1 2026.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.